The experimental enhancement of TGFβ/Activin signaling in animal models exacerbates pulmonary vascular remodeling mimicking PAH pathology [8] and reduction of TGFβ signaling through genetic or pharmacological intervention was efficacious in reversing the vascular remodeling in PAH animal models [5, 9]. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.